1. Background {#sec1}
=============

Osteoarthritis (OA) is the most common musculoskeletal disease, ranking as the 11th highest contributor to global disability and 38th highest in the disability-adjusted life years (DALYs) in the Global Burden of Disease 2010 study \[[@B1], [@B2]\]. About 18% of women and 10% of men over 60 years of age suffered from OA and had higher mortality rates than their peers \[[@B3], [@B4]\]. In recent studies, the pathological processes of OA involve several local and systemic factors such as cytokines, chemokines, inflammatory mediators, matrix degradation, cell-derived, and/or matrix-derived products, which may cause damages to the synovium, cartilage, subchondral bone, periarticular muscles, ligaments, and other joint structures and finally lead to pain, stiffness, and disability \[[@B5], [@B6]\]. At present, the medical management of OA includes surgical therapies and nonsurgical therapies such as intra-articular injection, medication, and physical therapy. However, it was still difficult to reverse the destruction of joint structures \[[@B5]\]. Therefore, it is of great clinic significance to find an ideal method to relieve pain, improve function, and delay the disease progression.

As a new technique, extracorporeal shockwave therapy (ESWT) uses a single-impulse transient acoustic wave induced by pneumatic, electrohydraulic, electromagnetic, or piezoelectric generators which focuse on the area needed to be treated \[[@B7]\]. ESWT has shown an effect on articular cartilage and subchondral bone development, neovascularization, tissue regeneration, and inflammatory response in some animal experiments \[[@B8]--[@B10]\]. ESWT also succeeds in the treatment of several musculoskeletal diseases, including tennis elbow syndrome, plantar fasciitis, tendon disease, and fracture nonunions, in some clinical studies \[[@B11]--[@B14]\]. More and more attention has been paid to the application of ESWT on OA because of its noninvasive nature, low rate of complications, and low cost compared with other surgical or conservative treatments in recent studies \[[@B15], [@B16]\]. Despite some systematic reviews focusing on the effect of ESWT on knee OA \[[@B17]--[@B19]\], there was no systematic review to confirm the value of EWST in the treatment of all types of OA (including knee OA and carpometacarpal joint OA) and compare ESWT with other traditional therapies (especially traditional Chinese medicine). Thus, this meta-analysis was performed, and the latest randomized controlled trials were included, which would contribute to the treatment of OA.

2. Method {#sec2}
=========

2.1. Search Strategy {#sec2.1}
--------------------

The protocol was registered in the PROSPERO database ([CRD42019120534](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42019120534)), and all searched results were evaluated according to the PRISMA statement. PubMed, MEDLINE, the Cochrane Central Register of Controlled Trials, Web of Science (WOS), Chinese National Knowledge Infrastructure (CNKI), WANFANG database, and VIP database were searched up to December 10, 2019, to identify the potential studies exploring the effect of ESWT for the treatment of OA. The searching strategy used was as follows: (((extracorporeal shock wave therapy \[Title/Abstract\]) OR ESWT\[Title/Abstract\])) AND ((osteoarthritis\[Title/Abstract\]) OR OA\[Title/Abstract\]) Filters: Publication date to 2019/12/10. The publication language was limited to English and Chinese.

2.2. Study Selection {#sec2.2}
--------------------

The inclusion criteria were the following: (1) randomized controlled trials (RCT) comparing the effect of ESWT and other treatments (including placebo) for all types of OA; (2) full text available and the outcome of experiments including mean (M), standard deviation (SD), and number (*N*); (3) patients aged 45 years or more and diagnosed with OA according to any clinical criteria; and (4) ESWT that had never been performed to the enrolled patients before.

The exclusion criteria were the following: (1) meta-analyses, reviews, letters, editorials, expert opinions, case reports, and nonrandomized control trials; (2) animal experiments; (3) patients with coagulopathy, pregnancy, cancer, history of fractures, cardiac pacemaker use, and neurologic conditions; and (4) including only the latest information if data were duplicated or overlapped.

2.3. Screening and Data Collection {#sec2.3}
----------------------------------

Two researchers independently assessed the eligibility of the studies, and the disagreements were resolved by a third verdict. Titles and abstracts were screened to identify the related studies, and then full texts were assessed carefully. Moreover, the references cited in the selected articles were explored to identify the potentially relevant studies. The scores of visual analogue scale (VAS) were extracted as primary outcome. Secondary outcomes included the scores of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), which represented the functional change. If the scores were recorded in different follow-up times, we selected the time point at 3 months or available data to be nearest to 3 months to predict the efficacy.

2.4. Quality Assessment {#sec2.4}
-----------------------

The quality of included studies was assessed by the Cochrane Collaboration\'s tool for assessing the risk of bias which was recommended for systematic reviews of interventions in Cochrane Handbook version 5.1.0 \[[@B20]\]. We evaluated 7 domains of bias including selection bias, performance bias, detection bias, attribution bias, reporting bias, and other sources of bias. The judgements were expressed as "high risk," "low risk," or "unclear risk," and the quality assessment figure was generated by RevMan version 5.3.

2.5. Statistical Analyses {#sec2.5}
-------------------------

Meta-analysis Review Manager software (RevMan version 5.3; The Cochrane Collaboration 2014) and STATA (version 12.0; Stata Corporation) were used for data analysis. The analysis was performed in two respects including pain reduction and functional improvement. The heterogeneity was evaluated by Higgins I2 statistic, *I*^2^ \> 50% was defined as significant heterogeneity among studies, and the random effects model was applied for the pooled effect estimates. Otherwise, the fixed effects model was used. At the same time, subgroup analysis was used for exploring sources of heterogeneity and reassessing the results. Sensitivity analyses were performed by removing an individual study from the meta-analysis each time. If more than 10 studies were included in each meta-analysis, the possibility of publication bias would be evaluated by Egger\'s test and *P* \< 0.05 was considered statistically significant; then the fill method and nonparametric trim were applied to correct the effect size. The results were expressed as the standard mean difference (SMD) and 95% confidence interval (95% CI) for continuous outcome data.

3. Result {#sec3}
=========

3.1. Search Results {#sec3.1}
-------------------

As shown in [Figure 1](#fig1){ref-type="fig"}, the initial search yielded 549 articles and 173 records were screened after removing duplicates. The title and abstract of potentially relevant studies were read carefully, and 118 records were excluded. Then 55 full-text articles were assessed, and 23 articles were excluded because they did not meet the inclusion criteria. Finally, 32 RCTs were included in this meta-analysis \[[@B21]--[@B52]\]. Characteristics of these studies are shown in [Table 1](#tab1){ref-type="table"}. All of the articles were published between 2013 and 2019 in English or Chinese. The sample size ranged from 18 to 160. All experimental groups received ESWT, while control groups received different treatments including placebo \[[@B22], [@B23], [@B25], [@B26], [@B28], [@B30], [@B34], [@B48], [@B49], [@B51], [@B52]\], medication \[[@B31], [@B32], [@B43], [@B44], [@B50]\], intra-articular injections \[[@B21], [@B26], [@B27], [@B29], [@B35], [@B36], [@B39], [@B40]\], traditional Chinese medicine \[[@B38], [@B41], [@B42], [@B45], [@B46]\], ultrasound \[[@B22], [@B24], [@B47]\], surgery \[[@B33]\], and kinesiotherapy (KIN) \[[@B37]\].

3.2. ESWT vs. Placebo {#sec3.2}
---------------------

A statistically significant difference between ESWT group and placebo group was found in pain reduction (SMD = ‐1.44, 95% CI: -1.77 to -1.10, *P* \< 0.00001) and functional improvement (SMD = ‐1.84, 95% CI: -2.47 to -1.20, *P* \< 0.00001). As shown in [Figure 2](#fig2){ref-type="fig"}, high heterogeneity was observed in the analysis of pain reduction (*I*^2^ = 72%). After removing a study \[[@B25]\] from the meta-analysis, the heterogeneity decreased to 0%. The same phenomenon occurred in the analysis of functional improvement; the heterogeneity decreased from 89% to 30% after removing two studies \[[@B25], [@B26]\] from the meta-analysis, which suggested these two studies might be the sources of heterogeneity. The pooled effect did not change after removing these studies (*P* \< 0.00001), which indicated the result was robust.

3.3. ESWT vs. Intra-Articular Injections {#sec3.3}
----------------------------------------

As shown in [Figure 3](#fig3){ref-type="fig"}, there was a statistical difference between the ESWT group and hyaluronic acid intra-articular injection (HA) group in pain reduction (SMD = ‐0.39, 95% CI: -0.77 to -0.01, *P* = 0.04) and functional improvements (SMD = ‐0.64, 95% CI: -1.24 to -0.04, *P* = 0.04). The heterogeneity decreased after subgroup analysis, which suggested that the language and dose of HA might be potential sources of heterogeneity.

A statistically significant difference between the ESWT group and platelet-rich plasma (PRP) intra-articular injection group was observed in pain reduction (SMD = ‐0.40, 95% CI: -0.76 to -0.03, *P* = 0.03). However, there was no statistically significant difference in functional improvement (SMD = ‐0.02, 95% CI: -0.38 to 0.33, *P* = 0.89).

There was a statistically significant difference between the ESWT group and corticosteroid intra-articular injection group in pain reduction (SMD = ‐1.68, 95% CI: -2.41 to -0.95, *P* \< 0.00001) and functional improvements (SMD = ‐7.87, 95% CI: -9.78 to -5.95, *P* \< 0.00001).

3.4. ESWT vs. Medication {#sec3.4}
------------------------

There was a statistically significant difference between the ESWT group and medication group in the pain reduction (SMD = ‐1.67, 95% CI: -2.38 to -0.97, *P* \< 0.00001) and functional improvement (SMD = ‐1.09, 95% CI: -1.33 to -0.85, *P* \< 0.00001). High heterogeneity was found in pain reduction (*I*^2^ = 88%). In functional improvement, no heterogeneity was observed (*I*^2^ = 0%) ([Figure 4](#fig4){ref-type="fig"}).

3.5. ESWT vs. Ultrasound {#sec3.5}
------------------------

As shown in [Figure 5](#fig5){ref-type="fig"}, a statistically significant difference was observed between the ESWT group and ultrasound group in pain reduction (SMD = ‐0.65, 95% CI: -0.92 to -0.37, *P* \< 0.00001) and functional improvement (SMD = ‐1.48, 95% CI: -1.80 to -1.17, *P* \< 0.00001). No heterogeneity was observed in this meta-analysis (*I*^2^ = 0%).

3.6. ESWT vs. Surgery {#sec3.6}
---------------------

There was no statistically significant difference between the ESWT group and acupotomy surgery group in functional improvement (SMD = 0.31, 95% CI: -0.21 to 0.83, *P* = 0.24). ([Figure 6](#fig6){ref-type="fig"})

3.7. ESWT vs. KIN {#sec3.7}
-----------------

In [Figure 7](#fig7){ref-type="fig"}, a statistically significant difference was observed between the ESWT group and kinesiotherapy (KIN) group in functional improvement (SMD = ‐2.11, 95% CI: -2.90 to -1.32, *P* \< 0.00001).

3.8. ESWT vs. Traditional Chinese Medicine {#sec3.8}
------------------------------------------

As shown in [Figure 8](#fig8){ref-type="fig"}, there was no statistically significant difference between the ESWT group and manipulation group in pain reduction (SMD = 0.40, 95% CI: -0.23 to 1.03, *P* = 0.21) and functional improvement (SMD = ‐0.47, 95% CI: -1.71 to 0.76, *P* = 0.45). A statistically significant difference was found in comparison between the ESWT group and fumigation group in functional improvement (SMD = ‐1.28, 95% CI: -1.74 to -0.81, *P* \< 0.00001) but not in pain reduction (SMD = ‐0.29, 95% CI: -0.80 to 0.22, *P* = 0.26). There was a statistically significant difference between the ESWT group and acupoint moxibustion group in functional improvement (SMD = ‐0.60, 95% CI: -1.12 to -0.09, *P* = 0.02).

3.9. Adverse Event {#sec3.9}
------------------

Only temporary pain, minor bruising, or transient soft tissue swelling was observed in nine studies \[[@B25], [@B30], [@B34], [@B42], [@B44], [@B47], [@B50]--[@B52]\]. No adverse events were observed during the treatment in other six studies \[[@B27], [@B29], [@B36]--[@B38], [@B46]\], and the remaining studies did not mention it.

3.10. Sensitivity Analysis {#sec3.10}
--------------------------

In meta-analysis comparing ESWT with placebo, a single study was excluded each time to evaluate the impact of the individual data on the whole result. The results showed that the pooled effect was robust and no significant deviation from the overall results was detected in our study ([Figure 9](#fig9){ref-type="fig"}).

3.11. Quality Assessment and Publication Bias {#sec3.11}
---------------------------------------------

In quality assessment ([Figure 10](#fig10){ref-type="fig"}), 19 studies were considered to be high risk in blinding of participants and personnel because the therapeutic properties make it hard to apply blinding. 155 of 224 domains (69.2%) were determined at low risk, and 50 of 224 domains (22.3%) were determined at unclear risk. There was no publication bias in this meta-analysis (pain reduction---Begg\'s test: *P* = 0.161, Egger\'s test: *P* = 0.346; functional improvement---Begg\'s test: *P* = 0.466, Egger\'s test: *P* = 0.155).

4. Discussion {#sec4}
=============

This meta-analysis included 32 studies involving 2408 patients to explore the efficacy and safety of ESWT for the treatment of OA. In this study, the ESWT group showed a statistically significant difference compared with the placebo, corticosteroid, HA, medication, and ultrasound group in both pain reduction and functional improvement, presenting that ESWT might be a successful alternative treatment when above treatments are unavailable. In functional improvement, ESWT showed statistical improvement compared with kinesiotherapy and moxibustion but no statistical difference compared with acupotomy surgery. A significant difference between ESWT and PRP was observed in pain reduction but not in functional improvement. Meanwhile, a statistical difference was found between ESWT and fumigation in functional improvement but not in pain reduction. Additionally, there was no statistically significant difference between ESWT and manipulation in both pain reduction and functional improvement. No serious adverse reaction occurred in all of studies.

Osteoarthritis (OA) is the most common cause leading to musculoskeletal pain \[[@B53]\]. It is considered that the pathological features of OA include articular cartilage destruction, subchondral bone change, osteophyte formation remolding, ligamentous laxity, periarticular muscle weakness, and synovial inflammation, which could result in chronic pain, physical limitation, and joint stiffness \[[@B54], [@B55]\].

Traditional treatments of OA included nonsurgical therapies and surgical therapies. In the 2014 Osteoarthritis Research Society International guidelines for the management of knee OA, nonsurgical therapies included intra-articular corticosteroids, biomechanical interventions, exercise, education and self-management, weight management, and strength training \[[@B56]\]. Traditional surgical options included joint sparing procedures such as arthroscopic surgery or joint replacing procedures \[[@B57]\]. For treatment, nonsurgical therapy might have limited benefit and could be associated with serious adverse events such as bleeding or gastrointestinal ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs) and infection caused by intra-articular injection \[[@B58]\]. As for surgery, it might be inappropriate for aged patients with limiting comorbidities. In such conditions, an effective and safe treatment was needed for patients with OA.

ESWT has been increasingly used in clinical practice over the past few years and shows significant efficacy in some clinical studies \[[@B16], [@B59]--[@B61]\]. It is suggested that ESWT can generate radial or focused pressure waves which bring energy and propagate through tissue \[[@B62]\]. This physical force could stimulate biological effects in a treated area, and the biochemical mechanism of ESWT in OA might be associated with neovascularization, osteogenesis, and chondrogenesis \[[@B63]--[@B65]\]. In recent studies, ESWT might lead to upregulation of angiogenic growth factors including endothelial nitric oxide synthase (eNOS) and vessel endothelial growth factor (VEGF), which benefit to neovascularization \[[@B66]\]. ESWT was also found connected with osteogenic transcription factors including VEGF-A and hypoxia inducible factor-1*α* (HIF-1*α*), affecting growth of osteoblasts \[[@B67]\]. Meanwhile, ESWT might elevate levels of nitric oxide (NO), bone morphogenetic protein-2 (BMP-2), protein kinase B (PKB), and transforming growth factor-beta 1 (TGF-*β*1), which facilitate differentiation and proliferation of osteoblasts \[[@B68]--[@B71]\]. Also, it was suggested that ESWT could enhance the expression of Pdia-3, a key point of 1*α*,25-dihydroxyvitamin D3 (1*α*,25(OH)~2~D~3~) signaling pathway \[[@B72]\]. This signaling pathway is essential in gene transcription and calcium homeostasis, which was considered beneficial for osteogenesis \[[@B73]\]. Besides, ESWT was revealed to have a dose-dependent effect on the metabolism of mesenchymal stem cells (MSCs), which potentially improve bone regeneration and chondrogenesis \[[@B74]\]. However, the exact mechanism of ESWT is still unknown, and further studies are required for better clinical utilization.

This study also had some limitations. First, we only searched studies in English and Chinese; thus, some potential relative studies in other languages might have been missed. Second, unreported negative results and gray literature could result in publication bias. Third, very few studies compared ESWT with surgery, PRP, and corticosteroid intra-articular injections, traditional Chinese medicine, or kinesiotherapy; thus, the subgroup analysis and sensibility analysis could not be performed, and the outcome might be misleading. Besides, in this meta-analysis, focused ESWT was performed in 8 studies in the experiment group and radial ESWT was administered in 19 studies, while the type of ESWT was unmentioned in the other 5 studies. As a result, it was difficult to perform subgroup analysis according to the different type of ESWT and analyze whether there was a difference between the focused ESWT and radial ESWT in the treatment of OA. Further studies could be carried out to improve this issue.

5. Conclusion {#sec5}
=============

In conclusion, ESWT showed a significant effect in the treatment of OA in pain reduction or/and functional improvement compared with placebo, corticosteroid, HA, medication, ultrasound, moxibustion, fumigation, PRP, and kinesiotherapy. However, ESWT failed to show a statistically significant difference compared with manipulation and surgery. As a result, ESWT could be recommended in the treatment of OA as a noninvasive therapy with safety and effectiveness but the grade of recommendations needs to be discussed in a further study.
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###### 

Basic characteristics of included studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                    Publication year   Country   Language   Sample size   Control group                                    Experimental group    Outcome measures   Follow-up time    Type of OA              Type of ESWT
  ----------------------------------------- ------------------ --------- ---------- ------------- ------------------------------------------------ --------------------- ------------------ ----------------- ----------------------- --------------
  Ediz                                      2018               Turkey    English    73            Placebo                                          ESWT 2 times/week\    VAS, WOMAC         6 M               Knee                    Focused ESWT
                                                                                                                                                   Total of 5 weeks                                                                   

  Ioppolo                                   2018               Rome      English    58            HA (3 injections of 0.5 cm^3^ HA)\               ESWT 1 time/week\     VAS                3 M               Carpometacarpal joint   Focused ESWT
                                                                                                  1 time/week\                                     Total of 3 weeks                                                                   
                                                                                                  Total of 3 weeks                                                                                                                    

  Lee                                       2017               Korea     English    61            HA (1 injection of 2 mL of HA) 1 time/week\      ESWT 1 time/week\     VAS, WOMAC         3 M               Knee                    Focused ESWT
                                                                                                  Total of 3 weeks                                 Total of 3 weeks                                                                   

  Lizis                                     2017               Poland    English    40            KIN 1 time/week\                                 ESWT 1 time/week\     WOMAC              5 W               Knee                    Unmentioned
                                                                                                  Total of 3 weeks                                 Total of 5 weeks                                                                   

  Zhao                                      2013               China     English    70            Placebo                                          ESWT 1 time/week\     VAS, WOMAC         3 M               Knee                    Radial ESWT
                                                                                                                                                   Total of 4 weeks                                                                   

  Liu Y                                     2016               China     Chinese    86            Placebo                                          ESWT 1 time/week\     VAS, WOMAC         3 M               Knee                    Radial ESWT
                                                                                                                                                   Total of 8 weeks                                                                   

  Liu MY                                    2017               China     Chinese    158           Medication (celecoxib) oral 200 mg qd\           ESWT\                 VAS, WOMAC         3 M               Knee                    Unmentioned
                                                                                                  4 weeks                                          1 time/week\                                                                       
                                                                                                                                                   Total of 4 weeks                                                                   

  Zhang                                     2017               China     Chinese    106           Ultrasound 5 times/week\                         ESWT 1 time/5 days\   VAS                1 M               Knee                    Radial ESWT
                                                                                                  Total of 4 weeks                                 Total of 5 times                                                                   

  Zheng                                     2016               China     Chinese    48            Medication (celecoxib) oral 200 mg qd\           ESWT 1 time/week\     VAS, WOMAC         1 M               Knee                    Radial ESWT
                                                                                                  4 weeks                                          Total of 4 weeks                                                                   

  Liu WT                                    2017               China     Chinese    58            Acupotomy surgery                                ESWT\                 WOMAC              5 W               Knee                    Unmentioned
                                                                                                                                                   1 time/5 days\                                                                     
                                                                                                                                                   Total of 6 times                                                                   

  ZhaoAQ                                    2016               China     Chinese    60            Placebo                                          ESWT\                 VAS, WOMAC         2 M               Knee                    Unmentioned
                                                                                                                                                   1 time/week\                                                                       
                                                                                                                                                   Total of 8 weeks                                                                   

  Wu                                        2014               China     Chinese    53            Medication (toricoxi) oral 60 mg qd\             ESWT\                 VAS                6 W               Knee                    Radial ESWT
                                                                                                  4 weeks                                          1 time/week\                                                                       
                                                                                                                                                   Total of 4 weeks                                                                   

  Chen                                      2014               China     English    120           Placebo\                                         ESWT 1 time/week\     VAS                2 M               Knee                    Focused ESWT
                                                                                                  Ultrasound 3 times/week\                         Total of 6 weeks                                                                   
                                                                                                  Total of 8 weeks                                                                                                                    

  Lee JH                                    2017               Korea     English    20            Placebo                                          ESWT 3 times/week\    VAS\               1 M               Knee                    Focused ESWT
                                                                                                                                                   Total of 4 weeks      WOMAC                                                        

  Zhong                                     2019               China     English    63            Placebo                                          ESWT 1 time/week\     VAS\               3 M               Knee                    Radial ESWT
                                                                                                                                                   Total of 4 weeks      WOMAC                                                        

  Wang                                      2016               China     Chinese    78            Massage manipulation 1 time/2 days\              ESWT 1 time/5 days\   WOMAC              3 M               Knee                    Radial ESWT
                                                                                                  10 weeks                                         Total of 5 weeks                                                                   

  Zhong                                     2018               China     Chinese    63            Placebo                                          ESWT 1 time/week\     VAS\               5 W               Knee                    Radial ESWT
                                                                                                                                                   Total of 4 weeks      WOMAC                                                        

  Xie                                       2019               China     Chinese    60            Fumigation bid 3 weeks                           ESWT 1 time/week\     VAS                3 M               Knee                    Radial ESWT
                                                                                                                                                   Total of 4 weeks                                                                   

  Su                                        2018               China     Chinese    160           HA (1 injection of 2 mL of HA) 1 time/week\      ESWT 1 time/week\     VAS\               5 W               Knee                    Radial ESWT
                                                                                                  Total of 5 weeks                                 Total of 5 weeks      WOMAC                                                        

  Su                                        2019               China     Chinese    120           PRP (1 injection of 4 mL of PRP) 1 time/week\    ESWT 1 time/week\     VAS\               5 W               Knee                    Radial ESWT
                                                                                                  Total of 5 weeks                                 Total of 5 weeks      WOMAC                                                        

  Qi                                        2015               China     Chinese    60            Acupoint moxibustion qd\                         ESWT 1 time/week\     WOMAC              6 M               Knee                    Focused ESWT
                                                                                                  4 weeks                                          Total of 4 weeks                                                                   

  Yang                                      2017               China     Chinese    86            Fumigation qd\                                   ESWT 1 time/5 days\   WOMAC              After treatment   Knee                    Radial ESWT
                                                                                                  16 days                                          Total of 4 weeks                                                                   

  Liu ZC                                    2019               China     Chinese    77            HA (1 injection of 2.5 mL of HA) 1 time/week\    ESWT 1 time/week\     VAS\               5 W               Knee                    Radial ESWT
                                                                                                  Total of 5 weeks                                 Total of 5 weeks      WOMAC                                                        

  Wu TY                                     2018               China     Chinese    100           Medication (celecoxib) oral 200 mg qd\           ESWT\                 VAS\               After treatment   Knee                    Radial ESWT
                                                                                                  4 weeks                                          1 time/week\          WOMAC                                                        
                                                                                                                                                   Total of 4 weeks                                                                   

  Cai                                       2018               China     Chinese    90            HA (1 injection of z.5 mL of HA)\                ESWT 1 time/week\     VAS\               3 M               Knee                    Radial ESWT
                                                                                                  1 time/week\                                     Total of 5 weeks      WOMAC                                                        
                                                                                                  Total of 5 weeks                                                                                                                    

  Wei                                       2018               China     Chinese    40            Massage manipulation 3 times/week\               ESWT 1 time/week\     VAS\               6 W               Knee                    Radial ESWT
                                                                                                  Total of 4 weeks                                 Total of 4 weeks      WOMAC                                                        

  Cho                                       2016               Korea     English    18            Placebo                                          ESWT 1 time/week\     VAS                1 W               Knee                    Focused ESWT
                                                                                                                                                   Total of 3 weeks                                                                   

  Liu YX                                    2018               China     Chinese    72            HA (1 injection of 20 mg of HA)\                 ESWT 2 times/week\    VAS\               2 M               Knee                    Unmentioned
                                                                                                  1 time/week\                                     Total of 2 months     WOMAC                                                        
                                                                                                  Total of 2 months                                                                                                                   

  Liu BZ                                    2019               China     Chinese    63            Placebo                                          ESWT 1 time/week\     VAS\               3 M               Knee                    Radial ESWT
                                                                                                                                                   Total of 4 weeks      WOMAC                                                        

  Elerian                                   2016               Egypt     English    60            Placebo corticosteroid injection 1 time/month\   ESWT\                 VAS\               2 M               Knee                    Radial ESWT
                                                                                                  Total of 2 months                                1 time/week\          WOMAC                                                        
                                                                                                                                                   Total of 3 weeks                                                                   

  Liu WF                                    2019               China     Chinese    66            Medication (celecoxib) oral 200 mg qd\           ESWT 1 time/week\     VAS                After treatment   Knee                    Radial ESWT
                                                                                                  4 weeks                                          Total of 4 weeks                                                                   

  Dou                                       2016               China     Chinese    121           Ultrasound                                       ESWT                  WOMAC              1 M               Knee                    Focused ESWT

  1 time/2 days for first two intervals\                                                                                                                                                                                              
  1 time/3 days for 2nd to 6th intervals\                                                                                                                                                                                             
  1 time/4 days for 6th to 8th intervals                                                                                                                                                                                              
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: RCT: randomized controlled trial; ESWT: extracorporeal shockwave therapy; HA: hyaluronic acid intra-articular injections; PRP: platelet-rich plasma; KIN: kinesiotherapy; VAS: visual analogue scale; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; W: weeks; M: months; qd: once a day; bid: twice a day; OA: osteoarthritis.
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